Go Pro
NASDAQ:IRTC

iRhythm Technologies Q2 2026 Earnings Report

iRhythm Technologies logo
$126.48 +1.95 (+1.57%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$126.48 -0.01 (0.00%)
As of 07/2/2026 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

iRhythm Technologies EPS Results

Actual EPS
N/A
Consensus EPS
-$0.01
Beat/Miss
N/A
One Year Ago EPS
N/A

iRhythm Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
$219.29 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

iRhythm Technologies Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Thursday, July 30, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

iRhythm Technologies Earnings Headlines

PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - including the ability to track every transaction or freeze funds. Martin D. Weiss, PhD, founder of Weiss Ratings, has identified 4 simple steps Americans can take today to help safeguard their savings before any changes take effect.tc pixel
See More iRhythm Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like iRhythm Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iRhythm Technologies and other key companies, straight to your email.

About iRhythm Technologies

iRhythm Technologies (NASDAQ:IRTC), Inc. is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders. After wearing the water-resistant patch, patients mail it back to iRhythm’s central lab, where recorded data are analyzed using the company’s AI-powered architecture. A comprehensive report, including annotated ECG strips and rhythm diagnosis, is delivered directly to the prescribing clinician, helping to guide treatment decisions.

iRhythm primarily serves the United States market through partnerships with hospitals, clinics and diagnostic laboratories, and the company has been expanding its global footprint through strategic collaborations and regulatory approvals in select international markets. Leadership is headed by President and Chief Executive Officer Kevin King, who has overseen product innovation and process enhancements to support scalable growth. iRhythm continues to invest in research and development to extend its diagnostic platform into emerging areas of cardiovascular care and digital health.

View iRhythm Technologies Profile